Apoptosis and cell-cycle arrest in human and murine tumor cells are initiated by isoprenoids.
Diverse classes of phytochemicals initiate biological responses that effectively lower cancer risk. One class of phytochemicals, broadly defined as pure and mixed isoprenoids, encompasses an estimated 22,000 individual components. A representative mixed isoprenoid, gamma-tocotrienol, suppresses the growth of murine B16(F10) melanoma cells, and with greater potency, the growth of human breast adenocarcinoma (MCF-7) and human leukemic (HL-60) cells. beta-Ionone, a pure isoprenoid, suppresses the growth of B16 cells and with greater potency, the growth of MCF-7, HL-60 and human colon adenocarcinoma (Caco-2) cells. Results obtained with diverse cell lines differing in ras and p53 status showed that the isoprenoid-mediated suppression of growth is independent of mutated ras and p53 functions. beta-Ionone suppressed the growth of human colon fibroblasts (CCD-18Co) but only when present at three-fold the concentration required to suppress the growth of Caco-2 cells. The isoprenoids initiated apoptosis and, concomitantly arrested cells in the G1 phase of the cell cycle. Both suppress 3-hydroxy-3-methylglutaryl CoA reductase activity. beta-Ionone and lovastatin interfered with the posttranslational processing of lamin B, an activity essential to assembly of daughter nuclei. This interference, we postulate, renders neosynthesized DNA available to the endonuclease activities leading to apoptotic cell death. Lovastatin-imposed mevalonate starvation suppressed the glycosylation and translocation of growth factor receptors to the cell surface. As a consequence, cells were arrested in the G1 phase of the cell cycle. This rationale may apply to the isoprenoid-mediated G1-phase arrest of tumor cells. The additive and potentially synergistic actions of these isoprenoids in the suppression of tumor cell proliferation and initiation of apoptosis coupled with the mass action of the diverse isoprenoid constituents of plant products may explain, in part, the impact of fruit, vegetable and grain consumption on cancer risk.
Mo
H
H
Department of Nutritional Sciences, University of Wisconsin-Madison, Madison, WI 53706, USA.
Elson
C E
CE
D000818:Animals; D017209:Apoptosis / Q000187:drug effects*; D001943:Breast Neoplasms / Q000188:drug therapy; D018938:Caco-2 Cells / Q000187:drug effects*; D002453:Cell Cycle / Q000187:drug effects; D016923:Cell Death / Q000187:drug effects*; D002839:Chromans / Q000627:therapeutic use*; D053938:DNA Fragmentation; D004587:Electrophoresis, Agar Gel; D005260:Female; D005434:Flow Cytometry; D016193:G1 Phase / Q000187:drug effects*; D018922:HL-60 Cells / Q000187:drug effects*; D006801:Humans; D034921:Lamin Type B; D034882:Lamins; D008546:Melanoma, Experimental / Q000188:drug therapy* / Q000473:pathology; D051379:Mice; D045792:Norisoprenoids; D009687:Nuclear Proteins / Q000187:drug effects; D013729:Terpenes / Q000627:therapeutic use*; D014407:Tumor Cells, Cultured / Q000187:drug effects*; D014810:Vitamin E / Q000031:analogs & derivatives* / Q000627:therapeutic use
D002839:Chromans; D034921:Lamin Type B; D034882:Lamins; D045792:Norisoprenoids; D009687:Nuclear Proteins; D013729:Terpenes; D014810:Vitamin E; C013649:plastochromanol 8; C008157:beta-ionone